KLOW Blend
Published research and evidence base
KLOW is a marketed combination of four peptides: BPC-157, TB-500 (a fragment-based thymosin beta-4 analogue), GHK-Cu and KPV. A systematic search of PubMed and Europe PMC returned no published study of this four-peptide blend in any model, and no pharmacokinetic, efficacy or safety data exist for the combination. The available literature is component-level: BPC-157 rests almost entirely on rodent work from a small number of laboratories with only two very small uncontrolled human pilot studies; thymosin beta-4 has two randomised phase 2 wound trials; KPV is supported by in vitro and animal anti-inflammatory work; and GHK-Cu is covered separately in this dataset. Only one published study examines any two of the components together.
- Studies cited
- 16
- Published 2023+
- 10
- Newest paper
- 2026
- Last reviewed
- Aug 2026
Recurring themes in the literature
- component-level evidence only
- no blend pharmacokinetics
- angiogenesis and granulation tissue formation
- actin sequestration and cell migration
- alpha-MSH-derived anti-inflammatory tripeptide
- unapproved injectable peptides in sports medicine
- compounded peptide quality and regulatory status
16 published studies.
Ordered by strength of study design, then by recency. Every entry links to its source record so the finding can be checked against the paper rather than taken on our word.
- 01Systematic review2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Vasireddi N, et al. · HSS Journal · systematic review of BPC-157 literature relevant to orthopaedic sports medicine
The review systematically collated the BPC-157 evidence base for musculoskeletal applications. It provides the most structured appraisal available of how much of that base is preclinical.
- 02Human clinical2025
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Lee E, et al. · Alternative Therapies in Health and Medicine · IRB-approved pilot, n=2 participants, 10 mg then 20 mg BPC-157 in 250 cc normal saline infused over one hour on consecutive days, private clinic
Two participants received intravenous BPC-157 with baseline and post-infusion bloods and vital signs. With n=2 and no control arm, the study cannot establish safety; the authors noted that few human studies of BPC-157 exist and none previously on intravenous use.
Reported safety finding. Only published human safety data for intravenous BPC-157; sample size of two makes it uninformative about risk.
- 03Human clinical2024
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Lee E, et al. · Alternative Therapies in Health and Medicine · uncontrolled pilot, n=12 women aged 39-76 (mean 58.3), BPC-157 from a 503A compounding pharmacy, private clinic
Twelve women with interstitial cystitis received compounded BPC-157 in an open-label pilot. The authors stated that BPC-157 is not FDA-approved; there was no placebo arm and the product was compounded rather than pharmaceutical grade.
Reported safety finding. Study product was supplied by a compounding pharmacy; BPC-157 has no FDA approval.
- 04Human clinical2021
Recombinant human thymosin beta-4 (rhTb4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.
Yu R, et al. · Microbial Biotechnology · human scalp study in seborrheic dermatitis with scalp microbiome profiling
Recombinant human thymosin beta-4 was associated with improved scalp condition and scalp microbiome homeostasis in seborrheic dermatitis. It is one of very few human cutaneous datasets for a thymosin beta-4 product.
- 05Human clinical2010
The effect of thymosin treatment of venous ulcers.
Guarnera G, et al. · Annals of the New York Academy of Sciences · double-blind, placebo-controlled, dose-escalation phase 2 trial, n=73 randomised across eight European sites (five Italy, three Poland)
Topical thymosin beta-4 was assessed for safety, tolerability and efficacy in venous stasis ulcers; the safety profile of all administered doses was deemed acceptable. This is the highest-tier human evidence for any KLOW component other than GHK-Cu.
- 06Animal in vivo2026
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
Bicer O, et al. · Joint Diseases and Related Surgery · 32 male Sprague-Dawley rats, Achilles tendon transection and repair, four groups (control, BPC-157 10 ug/kg/day, TB-500 60 ug/kg/day, combination), intraperitoneal dosing for 4 weeks
This is the only located study administering two KLOW components together. Tendons were assessed by maximum load to failure and by histological, histochemical and immunohistochemical analysis at four weeks. It concerns tendon rather than skin and does not include GHK-Cu or KPV.
- 07Animal in vivo2026
Low-Temperature Fabrication of Thymosin b4-Loaded Soluble Microneedles to Promote Wound Healing by Specific Binding to Downregulated Immune Regulators Vsig4 and IL22ra2.
He S, et al. · Advanced Healthcare Materials · thymosin beta-4-loaded dissolving microneedle patches in a wound-healing model
Thymosin beta-4 delivered by low-temperature-fabricated soluble microneedles promoted wound healing, with the effect linked to binding of the downregulated immune regulators Vsig4 and IL22ra2.
- 08Animal in vivo2025
Tb4-Engineered ADSC Extracellular Vesicles Rescue Cell Senescence Through Separable Microneedle Patches for Diabetic Wound Healing.
Ding Y, et al. · Advanced Science · diabetic wound model treated with thymosin beta-4-engineered adipose stem cell extracellular vesicles in separable microneedle patches
Extracellular vesicles from thymosin beta-4-engineered adipose-derived stem cells, delivered by separable microneedle patches, reduced cell senescence and improved diabetic wound healing.
- 09Animal in vivo2024
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
Rahaman KA, et al. · Journal of Chromatography B · in vitro metabolic incubations and rat dosing with UHPLC-Q-Exactive orbitrap MS/MS quantification, plus in vitro wound-healing screening
TB-500 and its metabolites were quantified in vitro and in rats and screened for wound-healing activity. The paper is one of the few to characterise TB-500 disposition rather than assume it matches full-length thymosin beta-4.
- 10Animal in vivo2021
In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis.
Shao W, et al. · Biomaterials Science · thermosensitive PLGA-PEG-PLGA hydrogel with EGCG delivering KPV in chemotherapy-induced oral mucositis
A mucoadhesive in situ hydrogel loaded with KPV was developed and evaluated for anti-inflammatory, antibacterial and mucosal repair effects in chemotherapy-induced oral mucositis.
- 11Animal in vivo2015
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.
Huang T, et al. · Drug Design, Development and Therapy · alkali burn rat skin model with topical BPC-157, plus in vitro proliferation, migration and angiogenesis assays
Topical BPC-157 accelerated wound closure after alkali burn, with better granulation tissue formation, re-epithelialisation, dermal remodelling and collagen deposition than controls at day 18, and increased VEGF expression in wounded skin. This is the principal cutaneous animal evidence for BPC-157.
- 12In vitro2025
Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway.
Sung J, et al. · Tissue and Cell · human HaCaT keratinocytes exposed to PM10 particulate matter
KPV at 50 ug/mL restored HaCaT viability and reduced IL-1beta secretion after PM10 exposure, and inhibited reactive oxygen species production upstream of ERK and p38 MAPK activation. The work is entirely cell-culture based.
- 13Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Mendias CL, et al. · Sports Medicine · review of approved and unapproved peptide therapies used for musculoskeletal injury and performance
The review appraised the safety and efficacy evidence for peptides marketed for musculoskeletal and performance use, a category that includes BPC-157 and TB-500. It is one of the most recent independent appraisals of the class.
Reported safety finding. Addresses the safety of unapproved peptide therapies used outside regulatory oversight.
- 14Review2026
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.
Yuan C, et al. · International Journal of Molecular Sciences · narrative review of BPC-157 in tissue repair and pain
The review summarised proposed mechanisms for BPC-157 across tissue repair and analgesia. The underlying primary literature it draws on is overwhelmingly rodent-based.
- 15Review2012
The regenerative peptide thymosin b4 accelerates the rate of dermal healing in preclinical animal models and in patients.
Treadwell T, et al. · Annals of the New York Academy of Sciences · review of thymosin beta-4 full-thickness punch wound studies in normal, steroid-treated, diabetic and aged rodents, plus two phase 2 clinical trials
Thymosin beta-4 accelerated dermal healing across several rodent models, and in two phase 2 trials of stasis and pressure ulcers accelerated healing by almost a month among those patients who did heal. The qualifier that the benefit applied only to patients who healed is an important limitation.
- 16Review2008
Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.
Brzoska T, et al. · Endocrine Reviews · comprehensive review of alpha-MSH and its C-terminal tripeptides including KPV
This is the foundational review establishing that the alpha-MSH C-terminal tripeptide KPV retains anti-inflammatory activity in vitro and in vivo without the pigmentary activity of the full hormone. It defines the mechanistic rationale for KPV in inflammatory skin conditions.
What this evidence does not establish.
No study of the KLOW four-peptide combination exists in any species, so there is no evidence on additive or interfering effects, no combined pharmacokinetics, no dosing rationale and no combination safety data. BPC-157 has never been tested in an adequately powered randomised controlled trial in humans; the only human data are two uncontrolled pilots (n=2 and n=12) published in a low-impact journal, one using compounded product. TB-500 is not identical to thymosin beta-4, and the phase 2 wound trials were conducted with full-length thymosin beta-4 rather than the fragment sold as TB-500. KPV has no published human trial in dermatology. None of these peptides is an approved medicine for a skin indication.
Common questions about the research.
- What is the research rationale for combining these four peptides?
The components occupy complementary niches in the repair literature: BPC-157 is studied for fibroblast migration and vascular recruitment, TB-500 for actin-mediated cell motility, GHK-Cu for collagen synthesis and matrix remodelling, and KPV for inflammation resolution. Blend vials exist because these mechanisms are frequently co-studied.
- Has the four-peptide KLOW combination been studied?
No. A systematic search of PubMed and Europe PMC returned no published study of the four-peptide blend in any model or species. There is no combined pharmacokinetic data, no evidence on additive or interfering effects, no dosing rationale and no combination safety data. Only one published study examines any two of the four components together.
- What did the one study of two KLOW components together report?
A 2026 experiment in 32 male Sprague-Dawley rats with Achilles tendon transection and repair compared a control group, BPC-157, TB-500 and a combination arm, with intraperitoneal dosing over four weeks. Tendons were assessed by maximum load to failure and by histological, histochemical and immunohistochemical analysis. The authors reported that combined treatment did not confer additional benefit over either peptide given alone.
- How mature is the evidence for the individual KLOW components?
It varies widely, and none of the four is an approved medicine for a skin indication. BPC-157 rests almost entirely on rodent work from a small number of closely affiliated laboratories, with human data limited to two uncontrolled pilot studies of 2 and 12 participants. Full-length thymosin beta-4 has two randomised phase 2 wound trials, but TB-500 is not identical to it and those trials used the full-length peptide. KPV is supported by in vitro and animal anti-inflammatory work with no published human dermatology trial, and the controlled human evidence for GHK-Cu is thin and inconsistent.
Available from our catalog
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no study summarised here should be read as a recommendation.